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A case of pregnancy with Rhesus antibody and





Introduction: In 1% of Rhesus negative women sensitisation occurs without any overt sensitising event during
pregnancy. This accounts for late immunisation during a first pregnancy and is responsible for 18-27% of cases of
alloimmunisation. The incidence of congenital uterine anomalies in a fertile population is 3.2% of which 5% are
bicornuate uterus. Bicornuate uterus can lead to early miscarriages, preterm labor, fetal growth retardation and
congenital malformations.
Case presentation: A 23-year-old lady in her first pregnancy developed Anti-D antibodies at 28 weeks of gestation
without any known sensitising event. In view of increasing anti-D titres, at 36 weeks she was delivered. Incidentally
during caesarean section she was found to have bicornuate uterus. The neonate was treated with phototherapy
and blood transfusion following delivery.
Conclusion: Rhesus antibodies when managed by close monitoring and timely delivery can lead to favourable
outcome. Bicornuate uterus does not always lead to complications like miscarriage, growth retardation or preterm
labour and does not need any special intervention.
Introduction
Human blood is classified according to two main sys-
tems: the ABO system and the Rhesus (Rh) system.
The Rh system consists of several related proteins, the
most important of which is called the Rhesus D (RhD)
antigen. People who have this antigen on their red
blood cells are said to be RhD positive, whereas those
who do not are said to be RhD negative. A baby inher-
its its blood type from both parents. Therefore a
mother who is RhD negative can carry a baby who is
RhD positive. During pregnancy small amounts of fetal
blood can enter the maternal circulation (an event
called feto-maternal haemorrhage or FMH). The pre-
sence of fetal RhD-positive cells in her circulation can
cause a mother who is RhD negative to mount an
immune response, producing a template for the pro-
d u c t i o no fa n t i b o d i e sa sw e l la ss m a l la m o u n t so fa n t i -
bodies against the RhD antigen (anti-D antibodies).
This process is called sensitisation or
alloimmunisation. Sensitisation is unlikely to affect the
current fetus but may result in haemolytic disease of
the newborn (HDN) during a second RhD-positive
pregnancy. These can be in situations in which FMH
is likely (after delivery, miscarriage, abortion, invasive
procedures or abdominal trauma) or even without any
known sensitising events in 1% of the cases. In fact the
most important cause of anti-D antibodies is now
immunisation during pregnancy where there has been
no overt sensitising event. Late immunisation during a
first pregnancy is responsible for 18-27% of cases. In
its mildest form the infant has sensitised red cells,
which are detectable only in laboratory tests; however,
HDN may result in jaundice, anaemia, developmental
problems or intrauterine death.
Routine antenatal anti-D prophylaxis (RAADP) can be
given to RhD-negative women to prevent sensitisation
and hence prevent HDN. A recent health technology
appraisal of RAADP forms the national guidance in the
UK that RAADP be offered to all non-sensitised preg-
nant women who are RhD negative [1]. * Correspondence: acharya.santanu@yahoo.com
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A 23-year-old British Asian lady presented in her first
pregnancy and had a dating scan in the first trimester.
She was fit and healthy and did not have any significant
medical or surgical history except mild asthma. All her
booking bloods were normal. Her blood group was O
Rhesus negative (C-c+E-e+K-). The antibody screen was
negative and as per our hospital protocol she was due
for another antibody check at 28 weeks’ gestation. Her
anatomy scan at 20 weeks was normal. Her pregnancy
went on uneventfully.
At her 28 week visit she was given 1500 IU of Anti-D
for prophylaxis. Blood taken for antibody screen surpris-
ingly showed Allo Anti-D levels of 3 IU/ml. She did not
have any history of trauma or blood transfusion which
could have made her sensitised. She was told that anti-
D levels of <4 IU/ml would be very unlikely to cause
haemolytic disease of the newborn (HDN). However,
she would from then on be under the care of a hospital
obstetric unit with close follow-up. Guidelines recom-
mended repeat testing every 2 weeks until delivery. Her
husband’s blood group was then checked and found to
be B Rhesus positive (C+c-E-e+K-). The Rh phenotype
indicated likely homozygous D expression, in which case
all his children were likely to inherit the D antigen.
Two weeks later repeat testing showed significant
increase in Anti-D levels at 8 IU/ml. Ultrasound scan
for growth and liquor volume was normal. In another
two weeks anti-D levels were 18 IU/ml. Levels above 15
IU/ml has a high risk of HDN. The HDN risk increases
if gestation continued beyond term. The pregnancy was
cautiously allowed to continue until 36 weeks with ster-
oid prophylaxis to attain fetal lung maturity. USS per-
formed showed normal growth and liquor volume.
Umbilical and middle cerebral artery dopplers were also
normal. After discussion with the patient induction of
labour was started at 36
+3 weeks of gestation. She was
given two doses of prostaglandin per vagina but with a
modified Bishop’s score of only 3 artificial rupture of
membranes was not possible. She declined further
attempt at induction of labour and underwent a Caesar-
ean section (CS).
Just before CS fetal heart was found to be decelerat-
ing. During CS it was found that she had bicornuate
uterus, which was not known beforehand, the pregnancy
being located in one of the horns of the uterus. The CS
was uneventful. A female baby weighing 2.6 Kg was
born. Apgar scores were 5 @ 1 min, 7 @ 5 min and 9 @
10 min. Blood gas analysis showed arterial PH 7.07, Base
excess (BE) - 5.9, venous PH 7.11, BE - 4.7. Neonatal
resuscitation involved bag and mask ventilation and the
baby was moved to Special Care Baby Unit. Cord blood
Direct Antibody Test (DAT) was performed which was
strongly positive. On day one following delivery hemo-
globin and bilirubin were 14.1 gm/dL and 59 μmol/L
respectively. The baby developed jaundice within the
first 24 hours. She gradually developed increasing serum
bilirubin levels and her haemoglobin also dropped.
Treatment involved phototherapy and blood transfusion.
However, she was discharged in good condition follow-
ing two weeks’ stay in the hospital when her anemia
and jaundice were corrected.
Discussion
Sensitisation can happen at any time during pregnancy,
but is most common in the third trimester and during
childbirth. Sensitisation can follow events in pregnancy
known to be associated with FMH but can also occur in
the absence of an observed potentially sensitising event.
The risk of sensitisation is greatest in the first pregnancy
and decreases with each subsequent pregnancy. Once
sensitisation has occurred it is irreversible. In our case
no known sensitising event was present to attribute for
the development of the allo-antibodies at 28 weeks of
gestation [1]. The diagnostic accuracy of non-invasive
fetal Rh determination using maternal peripheral blood
is 94.8%. Its use can be applicable to Rh prophylaxis and
to the management of Rh alloimmunized pregnancies
[2].
When red blood cells are broken down, bilirubin is
released. In utero this is cleared by the placenta and is
not harmful. However, after birth the neonatal liver can-
not cope with the excess production of bilirubin, and
this leads to jaundice (haemolytic disease of the new-
born or HDN). Low levels of jaundice are not harmful
but, if left untreated, higher levels can result in damage
to specific areas of the neonatal brain, causing perma-
nent brain damage (kernicterus). This can lead to a
range of neurodevelopmental problems, such as cerebral
palsy, deafness, and motor and speech delay. Postnatal
jaundice can be treated with phototherapy and exchange
transfusion. Our case was successfully managed by close
monitoring, phototherapy and blood transfusion.
The risk of RhD alloimmunisation during or immedi-
ately after a first pregnancy is about 1.5%. Administra-
tion of 100 ug (500 IU) anti-D at 28 weeks and 34
weeks gestation to women in their first pregnancy can
reduce this risk to about 0.2% without, to date, any
adverse effects. Although such a policy is unlikely to
confer benefit or improve outcome in the present preg-
nancy, fewer women will have Rhesus D antibodies in
their next pregnancy. Adoption of such a policy will
need to consider the costs of prophylaxis against the
costs of care for women who become sensitised and
their affected infants, and local adequacy of supply of
anti-D gammaglobulin [3]. Potentially sensitising events
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maternal circulation. The anti-D immunoglobulin admi-
nistered neutralises this fetal antigen. In addition, anti-D
immunoglobulin can be administered routinely in the
third trimester as prophylaxis against small amounts of
FMH that can occur in the absence of observable sensi-
tising events. This is known as routine antenatal anti-D
prophylaxis (RAADP). The use of anti-D immunoglobu-
lin for RAADP is in addition to the administration of
anti-D immunoglobulin following potentially sensitising
events, and its use in either indication is not affected by
prior use in the other [4].
This lady incidentally was found to have a bicornuate
uterus during CS (Figure 1). The incidence of congenital
uterine anomalies in a fertile population is 3.2%, 90% of
which are septate uterus and another 5% each are bicornu-
ate uterus and uterine didelphys [5]. A large case control
study by the Spanish Collaborative Study of Congenital
Malformations looked at 26945 consecutive malformed
infants and assessed the frequency of congenital anomalies
in offsprings of mothers with bicornuate uterus. The risk
of congenital defects was found to be four times higher in
mothers with bicornuate uterus in this study [6]. Another
retrospective longitudinal study on uterine anomalies
demonstrated live birth rates of 62.5% in cases of bicornu-
ate uterus but early miscarriages and preterm labour were
more common [7]. The cause for fetal distress in this case
just before CS was not known. However, bicornuate uterus
in this case had no untoward implication as far as this
pregnancy was concerned.
This case demonstrates that a favourable outcome is
possible in cases of Rhesus antibodies if proper monitor-
ing is done. It also suggests that women with bicornuate
uterus could have good reproductive prognosis without
any intervention.
Conclusion
Rhesus antibodies when managed by close monitoring
and timely delivery can lead to favourable outcome.
Bicornuate uterus does not always lead to complications
like miscarriage, growth retardation or preterm labour
and does not need any special intervention.
Patient’s perspective
My husband and myself was trying for a pregnancy for
the previous eight months so was very excited when
we found that I was pregnant. Everything was going on
well, except the bad morning sickness that I had, until
I was 28 weeks pregnant. At that point, the consultant
mentioned to me that my blood group was O negative
a n dIh a dr i s i n ga n t i - Dl e v e l sw h i c hw a sar i s kt om y
baby. After weeks of close monitoring I was finally
told I was going to be induced at 36 weeks. I was very
scared and nervous as I did not know what to expect.
I was induced for two days with two pessaries but
nothing happened. I requested a Caesarean section but
the doctors and midwives persuaded me not to and
carry on with the induction process. However, I was
adamant and felt I cannot carry on further with the
induction process. Finally the doctors agreed and I
underwent the Caesarean section under a spinal anaes-
thetic with my husband being present in theatres. Dr
Acharya performed my surgery and he was fantastic.
A tt h ee n do fs u r g e r yh et o l dm et h a tIh a dad o u b l e
uterus. I was shocked and very surprised since nobody
picked it up in any of my previous scans. I had never
heard of anyone having a double uterus before! I am a
little worried if it will affect any future pregnancies.
My baby girl Lailah Noor was born and weighed 5.11
lbs. She was taken straight to SCBU as she was
severely anaemic and became jaundiced. After two
units of blood transfusion baby Lailah is doing well
and gaining weight at present.
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Figure 1 Bicornuate uterus during Caesarean Section.T h i s
shows the bicornuate uterus delivered outside the abdominal cavity
during the operation.
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